publications 

GLP-1 Pipeline Update: November 2026

Quarterly view of the GLP-1 pipeline and anticipated indications

November 19, 2026

Editorial team

 

Maryam Tabatabai, PharmD
Editor-in-Chief
Associate Vice President, Clinical Information 


Carole Kerzic, RPh
Executive Editor
Drug Information Pharmacist Principal 


Nicole Kjesbo, PharmD, BCPS
Executive Editor
Clinical Program Development Director Senior, Pipeline 

DISCLAIMER

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Prime Therapeutics. 

All brand names are property of their respective owners.

Introduction 

Over a decade ago, the first injectable glucagon-like peptide-1 receptor agonist medication (GLP-1) for type 2 diabetes mellitus (T2DM) was approved by the Food and Drug Administration (FDA) for chronic weight management. Since then, several GLP-1s for obesity have also been approved for new indications, such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis, or MASH (Wegovy). Notably, two oral GLP-1 formulations (Wegovy and Foundayo) are now approved for weight loss. As researchers investigate other potential applications for GLP-1s, robust market growth is expected.  

Two GLP-1 FDA decisions to watch for the remainder of 2026 
  • Eli Lilly’s oral Foundayo for T2DM is expected in the fourth quarter of 2026.  
  • Novo Nordisk’s injectable, fixed-dose combination of semaglutide and cagrilintide, an amylin receptor agonist, for weight loss is expected in December 2026. 

Given the considerable continued expansion and innovation across the GLP-1 pipeline, Prime Therapeutics’ team of talented clinical experts is committed to actively monitoring emerging evidence and therapeutic developments. While evaluating the balance between benefits, risks and real-world outcomes is central to this work, delivering holistic, patient-centered care remains the cornerstone of our practice.  

Our GLP-1 Pipeline Update offers a timely clinical snapshot of innovation on the horizon. Read on to learn more, explore the FAQs below and check out the October issue of our Quarterly Drug Pipeline for deeper insights into anticipated therapies currently in development. 

Access the complete GLP-1 Pipeline Update table for November 2026.

GLP-1s by year and indication

*Generics available

GLP-1s by indication and year

*Generics available

Pipeline FAQs

Glossary